What question did this study set out to answer?

The aim is to determine the effect of intensive blood pressure control compared to standard control in adults with type 2 diabetes.

April 10, 2026Open Access

Intensive vs standard blood pressure control in adults with type 2 diabetes: a systematic review and GRADE-based meta-analysis

Key Result

Intensive blood pressure control (<130/80 mm Hg) in type 2 diabetes reduced the composite cardiovascular outcome (OR 0.82) and stroke risk (OR 0.62) versus standard control.

Key Points

The aim is to determine the effect of intensive blood pressure control compared to standard control in adults with type 2 diabetes.
Conducted a systematic review and meta-analysis following PRISMA guidelines
Analyzed randomized controlled trials comparing intensive blood pressure control with standard control
Primary outcome was a composite of nonfatal cardiovascular events and heart failure hospitalization
Secondary outcomes included microvascular complications and overall safety
Intensive blood pressure control significantly reduced the primary composite outcome (OR: 0.82) and stroke risk (OR: 0.62)
Reduction in retinopathy and albuminuria observed (both OR: 0.83)
No significant differences in all-cause mortality or renal failure
Diastolic BP-targeted trials showed greater reduction in mortality (OR: 0.52)

Structured PICO

Does intensive blood pressure control reduce cardiovascular and microvascular events in adults with type 2 diabetes?

Population

10 RCTs pooling 23,826 adults ≥35 years with type 2 diabetes (T2DM).

Intervention

Intensive blood pressure control (target <130/80 mm Hg)

Comparator

Standard blood pressure control (<140/90 mm Hg)

Outcome

Composite of nonfatal stroke, nonfatal myocardial infarction, cardiovascular (CV) death, or heart failure hospitalizationcomposite

Intensive blood pressure control (<130/80 mm Hg) in patients with type 2 diabetes significantly reduces cardiovascular events and microvascular complications without increasing serious adverse events compared to standard control.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Background: The optimal blood pressure (BP) target for older adults with type 2 diabetes (T2DM) remains controversial. This meta-analysis compares intensive BP control (IBPC) versus standard BP control in T2DM patients. Methods: Following PRISMA guidelines, we searched PubMed, Embase, and Cochrane Central through March 2025 for randomized controlled trials (RCTs) comparing IBPC (target 50%) or fixed-effects models ( I 2 ≤ 50%). Results: Ten RCTs ( n = 23 826) were included. IBPC significantly reduced the primary composite outcome (OR: 0.82, 95% CI: 0.74–0.91, P = 0.0001, I 2 = 0%) and stroke risk (OR: 0.62, 95% CI: 0.49–0.79, P = 0.0001). Microvascular benefits included reduced retinopathy (OR: 0.83, 95% CI: 0.71–0.97, P = 0.02) and albuminuria (OR: 0.83, 95% CI: 0.70–0.99, P = 0.03). No significant differences were observed in all-cause mortality (OR: 0.86, 95% CI: 0.71–1.04, P = 0.12), CV mortality (OR: 0.77, 95% CI: 0.53–1.11, P = 0.16), or renal failure (OR: 0.96, 95% CI: 0.34–2.69, P = 0.94). Subgroup analysis showed diastolic BP-targeted trials had greater mortality reduction (OR: 0.52, 95% CI: 0.33–0.83, P = 0.005) versus systolic BP-targeted trials ( P = 0.88). Serious adverse events did not differ between groups (OR: 1.28, 95% CI: 0.90–1.81, P = 0.17). Conclusion: In T2DM patients, IBPC reduces cardiovascular events and microvascular complications without increasing adverse events, supporting lower BP targets (<130/80 mm Hg). Diastolic BP control may offer additional mortality benefits.